The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

A bill filed in Springfield would allow doctors to prescribe some HIV medication without needing prior authorization.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

Dolutegravir is one of the most effective and safest HIV medicines and is used by millions of adults and adolescents living ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...